NCT06330441 Pancreatic Cancer Screening in a Population at High Risk
| NCT ID | NCT06330441 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Masaryk Memorial Cancer Institute |
| Condition | Pancreatic Ductal Adenocarcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 700 participants |
| Start Date | 2022-01-07 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 700 participants in total. It began in 2022-01-07 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Pancreatic cancer is one of the diseases with the worst prognosis, which is mainly due to the initial asymptomatic prognosis. Unfortunately, the incidence of this disease in the Czech Republic is still increasing. In a certain proportion of patients, it is possible to predict the disease, e.g. due to family burdens. Regular follow-up of such individuals is the subject of the SCREPAN study: "Pancreatic Cancer Screening in High-Risk Persons".
Eligibility Criteria
Inclusion Criteria: * willing to participate in the study * age 18+ * arms specific criteria: A: * chronic pancreatic disease in the context of cystic fibrosis or chronic pancreatitis * age 50+ B1: * confirmed Peutz-Jegherson syndrome (mutSTK11) + age over 35 years or 10 years earlier than pancreatic ductal adenocarcinoma was diagnosed in the youngest family member * familial melanoma syndrome (mutCDKN2A) + age over 40 years or 10 years before pancreatic ductal adenocarcinoma was diagnosed in the youngest family member * confirmed hereditary pancreatitis (mutPRSS1) + age over 40 years or 20 years after the first attack B2: * confirmed diagnosis of hereditary syndrome (Lynch syndrome /mutMLH1, mutMSH2, mutMSH6, mutPMS2, mutEPCAM/, HBOC /mutBRCA1, mutBRCA2, mutPALB2, mutATM/, familial adenomatous polyposis /mutAPC/, Li-Fraumeni syndrome /mutTP53/) * at least one relative with a diagnosis of pancreatic ductal adenocarcinoma in family anamnesis at the same time (Grade I or II relative) * age over 50 years, or 10 years before the pancreatic ductal adenocarcinoma was diagnosed in the youngest relative - which comes first C: * positive family anamnesis of pancreatic ductal adenocarcinoma without hereditary syndrome context * age 50+ or 10 years earlier than the youngest relative with pancreatic ductal adenocarcinoma - screening is recommended for all first-degree relatives of affected family members Exclusion Criteria: * Inability to undergo radical curative surgery for a pancreatic tumor. * Inability to undergo scheduled imaging examinations. * Incurable malignant cancer.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06330441 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Ductal Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06330441 currently recruiting?
Yes, NCT06330441 is actively recruiting participants. Contact the research team at martina.lojova@mou.cz for enrollment information.
Where is the NCT06330441 trial being conducted?
This trial is being conducted at Brno, Czechia.
Who is sponsoring the NCT06330441 clinical trial?
NCT06330441 is sponsored by Masaryk Memorial Cancer Institute. The trial plans to enroll 700 participants.